5–7 predominant half lives [Design Issues]

posted by Helmut Homepage – Vienna, Austria, 2018-05-03 14:12 (1314 d 21:31 ago) – Posting: # 18754
Views: 1,927

Hi Rajasekhar,

» Example: Tamsulosin
» how to fix number of days to dosing

Until (pseudo) steady state is achieved. See this post for an example of linear PK.
Which regulation are you “targeting”? For the FDA a multiple dose study is not required. Since the SmPC recommends intake after breakfast, according to the EMA’s GL the multiple dose study has to be performed in fed state.

» how to fix number of doses per day

According to the posology of the reference (for tamsulosin OAD after breakfast).

» My regular practice is if label/smpc states achievement of steady-state concentrations by the fifth day of once-a-day dosing for Tamsulosin, i will design the study state protocol with once a day dosing for five days.

Fine but copy/paste ≠ science. :-D

» […] i want to know the exact scientific rationale behind this.

Kudos. Steady state is practically reached after 5–7 predominant half lives (96.9–99.2% of theoretical steady state). Note that Flomax® is a CR-formulation (flip-flop PK, where ka < ke). Whereas the elimination half life (after IV or IR) is ~6–7 hours, the apparent one of the CR is substantially prolonged (see the FDA’s NDA approval; page 217 of the PDF).

For drugs with nonlinear PK (e.g., saturation of metabolizing enzymes, auto-induction or -inhibition) it is complicated. Consult with a pharmacokineticist.

Dif-tor heh smusma 🖖
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

 Admin contact
21,788 posts in 4,557 threads, 1,548 registered users;
online 10 (0 registered, 10 guests [including 4 identified bots]).
Forum time: Wednesday 10:44 CET (Europe/Vienna)

There is no adequate defense, except stupidity,
against the impact of a new idea.    Percy Williams Bridgman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz